Zenabis Global Inc. (TSX:ZENA) (“Zenabis” or the “Company“) today announced its financial results for the first quarter ended March 31, 2019 and provided an update on operations. This is Zenabis’ first quarterly financial report since the public listing of its shares in January of 2019.
“The public listing of our shares, and our recent graduation to the Toronto Stock Exchange, reflect the ambitions we have for our company, and are important milestones in the Zenabis growth story,” said Andrew Grieve, Chief Executive Officer of Zenabis. “We have successfully undertaken a range of tangible corporate development initiatives in the past several months, including securing key supply and distribution arrangements and additional licenses and approvals; expanding our product offerings across Canada, developing relationships in Europe; and obtaining financing to support our rapid growth. We also commenced providing monthly reports on our operations and look forward to continuing to update our shareholders and the broader investment community on our progress.”
“Since the legalization of cannabis in Canada last fall, it has become clear that the winners in this industry will be those who can produce reliable supply,” continued Mr. Grieve. “Despite being a new entrant in the cannabis market, we demonstrated a clear ability to expand production and cultivation output during the first quarter of 2019. Our April 2019output exceeded our design capacity by more than 31%, and our overall cultivation output was 63% greater than forecast. For the three harvests thus far in May, we have exceeded design capacity by 28%. With an additional harvest being accelerated from June into May, we anticipate further strong total cultivation performance in May relative to forecast. This outperformance demonstrates the capabilities of our experienced cultivation team, and the quality of our facilities across Canada.”
“Our results demonstrate progress towards our goal of becoming one of the largest licensed producers of medical and adult-use recreational cannabis in Canada. Building on the proven agricultural heritage and cultivation excellence of our predecessor company, Bevo Agro Inc., we are investing in initiatives that will grow our production to meet demand across our key markets, enhance value for our shareholders, and deliver value to all of our stakeholders. Looking ahead, we expect further growth from our cannabis operations, continued expansion of our facilities, and significant increases in cannabis revenue,” added Mr. Grieve.
Commenting on Zenabis’ revenue growth expectations for the second quarter of 2019, Mr. Grieve said, “We currently anticipate revenue from the plant propagation business to be in a range of $16 to $18 million, and net revenue from the cannabis business to be in the range of $10 to $12 million. Net cannabis revenue is subject to the timing of shipments. This net cannabis revenue does not yet include any meaningful impact from the production of oil products, as the third-party supply chain for oil products (including post processing) adds a considerable amount of time from cultivation to realization of revenue. This time differential is expected to be significantly reduced upon completion of post-processing and additional extraction capacity at Zenabis Delta. Currently, a significant amount of existing cannabis inventory is allocated to the third-party oil processing supply chain.”
First Quarter 2019 Highlights:
- Completed a reverse takeover (the “RTO”) of Bevo Agro Inc. by Sun Pharm Investments Ltd. to become Zenabis Global Inc. on January 8, 2019, and began trading on the TSX Venture Exchange (“TSXV”) under the symbol “ZENA” on January 10, 2019
- Entered into supply arrangements with the provinces of Alberta, Manitoba, Quebec and Prince Edward Island, expanding Zenabis’ supply arrangements to a total of eight provinces and one territory
- Through its subsidiary, Bevo, completed the acquisition of Topgro Holdings Ltd., which includes 10.4 acres of greenhouse on 50 acres of land in Aldergrove, British Columbia
- Added a new product line with the acquisition of 51% of Hilllsboro Corp Inc., a kombucha company with expertise in the creation of cultured tea beverages
- Entered into supply agreement with Shoppers Drug Mart, one of Canada’s most significant retailers
- Received approval to cultivate and grow cannabis at its 255,000 square foot facility in Stellarton, Nova Scotia, with the initial licensed area adding design capacity of 800 kilograms of dried cannabis per year
- Obtained a license to process and sell cannabis oil products in Canada, enabling Zenabis to sell cannabis oil produced at its Atholville, New Brunswick facility
- Achieved cultivation output of 1,472 kg, 11% greater than design capacity of 1,330 kg
- Achieved financial performance in line with ramp-up expectations, including:
- Total gross revenues of $12.3 million and net revenues of $11.6 million after excise taxes
- Gross margin before fair value adjustment of $3.9 million
- Operating expenses of $18.8 million
- Adjusted EBITDA1 of ($6.4 million)
- Net loss of $4.0 million
- Since the creation of Zenabis via the January 2019 RTO, more than doubled licensed production capacity from 6,000 kg to 13,400 kg as at May 30, 2019
- Delivered 31% outperformance relative to cultivation design capacity in April, with cultivation output of 809 kg, 63% greater than our forecast of 495 kg
- Received license approval for Phase 2A at the Atholville facility, adding 3,200 kg, or more than 30% to Zenabis’ total cannabis cultivation capacity
- Continued construction and licensing activity at both its Atholville and Langley facilities, with forecast annual production capacity of 131,300 kg by the end of the third quarter of 2019
- Expanded recreational cannabis product offerings to include pre-roll products under a new ultra-premium brand, Blazery, as well as pre-roll and oil products under its existing recreational brand, Namaste
- Entered into a binding term sheet for a three-year supply arrangement with leading German pharmaceutical research company Farmako GmbH (“Farmako”) for the supply of biosynthetically produced pure CBD isolate oil (99.9%) from Farmako to Zenabis for sale in Canada; and the supply of European Union Good Manufacturing Practices certified cannabis cultivated in Zenabis’ indoor facilities in Canada for sale by Farmako to the German medical market
- Graduated to the Toronto Stock Exchange (“TSX”) from the TSXV, effective on May 27, 2019, with the Company’s common shares and common share purchase warrants continuing to trade under the symbols “ZENA” and “ZENA.WT”, respectively
Summary First Quarter 2019 Financial Results
All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting.
For the quarter ended March 31, 2019, Zenabis recorded net revenues of $11.6 million, which was comprised primarily of $4.1 million and $7.5 million in Cannabis and Propagation segments, respectively, less inter-segment revenue of $0.3 million. Comparatively, in the three months ended December 31, 2018, the Company recorded net Cannabis revenue of $3.4 million, and in the three months ended March 31, 2018, the Company had not yet begun cannabis sales.
Gross margin before fair value adjustment totaled $3.9 million during the three months ended March 31, 2019, and includes $2.1 million and $1.6 million in Cannabis and Propagation gross margin, respectively, before fair value adjustments (51% and 21% as percent of net revenue by segment, respectively). Comparatively, in the three months ended December 31, 2018, Zenabis recorded a Cannabis gross margin before fair value adjustment of $1.7 million (50% of net revenue).
Total operating expenses for the quarter ended March 31, 2019 were $18.8 million, of which $4.9 were acquisition costs, which compares to $12.7 million in the three months ended December 31, 2018. Gain on the revaluation of derivative liability was $7.9 million in the 2019 first quarter compared to a loss of $13.1 million for Q4 2018, which was the result of fluctuations in the Company’s share price. Share-based compensation was $2.1 million in Q1 2019 compared to $4.6 million in Q4 2018, due to various options that were vested on an accelerated basis in the previous quarter, which was not the case in the current quarter. Finance and investment income was $1.1 million in Q1 2019 compared to a loss of $1.9 million in Q4 2018 due to an increase in the market value of investments held by the Company. Offsetting these amounts were $4.9 million in first quarter 2019 acquisition costs related to the RTO and other business acquisition transactions, compared to $74,900 in Q4 2018; Q1 2019 interest expense of $4.6 million compared to $1.2 million in Q4 2018, which was due to the additional debt the Company issued or assumed in late Q4 2018 and in Q1 2019; and depreciation and amortization of $1.5 million in Q1 2019 compared to $0.3 million in Q4 2018, which was primarily the result of the various facilities being ready and available for use.
Adjusted EBITDA1 has continued to show a loss due to the operational costs incurred by Zenabis to build-out its operational capacity to achieve the planned production capacity of its various facilities. Adjusted EBITDA has not improved in comparison to the three months ending December 31, 2018 due to the increase in operating costs which are primarily due to the development and implementation of the resources and capacity needed by the Cannabis segment to support the facilities under construction that will be producing in 2019. The additional expenses are partially offset by the increase in sales and margins realized through the Company’s Cannabis and Propagation segments. First quarter 2019 Adjusted EBITDA was ($6.4 million), compared to ($6.0 million) in Q4 2018.
The Company recorded a net loss for the three months ended March 31, 2019 of $4.0 million, or $0.02 loss per common share, compared to a net loss of $24.9 million, or $0.16 loss per common share, for the three months December 31, 2018.
Cash on hand increased to $25.6 million as at March 31, 2019 from $17.0 million at December 31, 2019. The increase in cash was mainly attributable to cash received from financing of $56.6 million, offset by cash used in operating activities of $17.6 million and investing activities of $30.3 million.
SOURCE Zenabis Global Inc.
IMCC Appoints Yaron Berger as CEO of IMC Holdings
IM Cannabis Corp. (the “Company” or “IMCC”) (CSE: IMCC), one of the world’s pioneering medical cannabis companies with operations across Europe, is pleased to announce the appointment of Yaron Berger as Chief Executive Officer of I.M.C. Holdings Ltd. (“IMC“), the Company’s wholly-owned operating subsidiary in Israel. Oren Shuster will remain the Chief Executive Officer of IM Cannabis Corp.
Mr. Berger brings more than 10 years of experience in various senior roles both in public and private sectors, leading large-scale operations. Most recently, Mr. Berger was the Chief Executive Officer of Telepharma Ltd. (“Telepharma,” doing business as epharma), a leading wholesaler, direct marketer of prescription drugs and chain of pharmacies in Israel. At Telepharma, among other accomplishments, Mr. Berger re-branded its digital platform and transformed the customer experience. As an early entrant into the medical cannabis sector, Mr. Berger also established Greenpharma under Telepharma, a full-service distributor, patient counselling service provider and online resource for medical cannabis patients in Israel. Prior to his experience in the pharmaceutical sector, Mr. Berger served as the Chief Operating Officer of the National Police Academy and spent over 20 years in the Israeli Air Force, most recently as a Lieutenant Colonel.
Oren Shuster, Chief Executive Officer of IMCC said “Yaron is uniquely qualified to lead our Israeli operations under the new medical cannabis regulatory regime, which requires a high level of engagement and education for the country’s pharmacists on the benefits of medical cannabis. Yaron was an early mover in identifying the opportunity in medical cannabis and we are very excited to benefit from his expertise in the pharmacy channel to maintain IMC’s status as a leading medical cannabis brand in Israel.”
“I am thrilled to be joining the IMC team, who I have known as a leader in the medical cannabis market in Israel over the past ten years,” said Mr. Berger. “The IMC brand is synonymous with quality and innovation. The new medical cannabis reform in Israel presents a significant opportunity for the Company and the IMC brand to further elevate its market position as the preferred medical cannabis brand for physicians, pharmacists and patients.”
SOURCE IM Cannabis Corp.
LCBO’s bottom line proves privatized alcohol sales a bad idea: OPSEU’s Thomas
The LCBO’s latest profits show the Crown corporation’s value to the people of Ontario, OPSEU President Warren (Smokey) Thomas said Friday.
In its 2018/2019 annual report released Thursday, the LCBO is reporting earnings of $2.37 billion on total revenue of $6.39 billion.
Thomas said those profits go to the provincial government and pay for vital public services like health, education and highways.
“This is why the Ford government should rethink allowing corner stores and grocery stores to sell more alcohol,” said Thomas. “Is saving folks a 10 minute drive in some cases worth jeopardizing their health care?”
OPSEU represents LCBO workers and Thomas says these frontline professionals deserve the credit for the corporation’s continued success.
“The reason the LCBO is the gold standard in selling alcohol responsibly is because of OPSEU members who make sure alcohol isn’t sold to minors or intoxicated people,” said Thomas.
“They also provide customer service that is second to none and they’re the ones who have made the LCBO a success story.”
As he read the LCBO report, OPSEU First Vice-President/Treasurer Eduardo (Eddy) Almeida reflected on the Ford government’s decision to take the sale of legalized cannabis away from the Crown Corporation.
“Think of what the LCBO’s profits would have been if Premier Ford hadn’t scrapped the plan of the former Liberal government?” said Almeida. “I’ve put together a lot of budgets and I know how tough an exercise it is.”
“It still makes me shake my head that a government that claimed it had catastrophic financial problems would turn down massive amounts of revenue and go on the misguided course that the Conservatives took. Really? Wow.”
Almeida says municipalities who voted to opt out of Doug Ford’s foolish cannabis privatization plan should stand firm and demand a responsible plan.
“The LCBO continues to prove it’s the best option to keep controlled substances out of the hands of minors,” said Almeida. “Municipalities and Ontarians in general should continue to demand a responsible plan and just say no to Doug’s. After all, a little competition wouldn’t be a bad thing would it?”
SOURCE Ontario Public Service Employees Union (OPSEU)
Base Oil Market Worth $39.6 Billion by 2024 – Exclusive Report by MarketsandMarkets™
According to the new market research report “Base Oil Market by Group (Group I, Group II, Group III, Group IV, Group V), Application (Automotive Oil, Industrial Oil, Hydraulic Oil, Grease, Metalworking Fluid), Region (North America, Europe, Asia Pacific, South America, MEA) – Global Forecast to 2024″, published by MarketsandMarkets™, the Base Oil Market is projected to grow from USD 33.7 billion in 2019 to USD 39.6 billion by 2024, at a CAGR of 3.3% from 2019 to 2024. The growing demand for high-grade oils in the automotive industry, as well as the increasing GDP in Asia Pacific driven by increasing industrial activities are key factors fuelling the growth of the base oil market across the globe.
Speak to Our Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=203695851
Browse in-depth TOC on “Base Oil Market”
150 – Tables
110 – Figures
480 – Pages
View Detailed Table of Content Here: https://www.marketsandmarkets.com/Market-Reports/base-oil-market-203695851.html
Group II segment to lead the base oil industry from 2019 to 2024
Based on group, the base oil market has been segmented into Group I, Group II, Group III, Group IV, and Group V. The Group II segment accounted for the major share of the market in 2018. Group II base oil can be employed in a multitude of applications, such as marine and gas engines, in trunk piston engine oils, and other applications in the base oil industry. The high consumption of Group II base oil is mainly attributed to its higher performance and affordability in comparison to the other groups of base oil. Thus, the Group II segment is likely to lead the market during the forecast period.
Automotive oil application segment to lead the base oil market during the forecast period
Based on application, the automotive oil segment led the base oil industry in 2018. This segment is also expected to witness significant growth during the forecast period owing to the rise of the automotive sector in developing countries, such as India and China. Population growth in the Asia Pacific region is increasing the demand for automobiles, which is, in turn, driving the market for automotive oils.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=203695851
Asia Pacific base oil market projected to witness the highest CAGR
Among regions, the Asia Pacific base oil market is projected to register the highest CAGR from 2019 to 2024. India, China, Indonesia, and Japan are key countries contributing to the increased demand for lubricants, and in effect base oil, in this region. Increasing GDP led by the rising industrial activities in Asia Pacific has increased the demand for base oil in the region. The growth of transportation, power generation, mining, and other sectors is also responsible for the rise in demand for base oil in the Asia Pacific region.
Chevron Corporation (US), Exxon Mobil Corporation (US), S-OIL Corporation (South Korea), Motiva Enterprises LLC (US), SK innovation Co., Ltd. (South Korea), Royal Dutch Shell plc (Netherlands), Neste Oyj (Finland), AVISTA OIL AG (Germany), Nynas AB (Sweden), Repsol S.A. (Spain), Ergon, Inc. (US), Calumet Specialty Products Partners, L.P. (US), H&R Group (Germany), Sinopec Corp. (China), PetroChina Company Limited (China), Saudi Aramco (Saudi Arabia), Abu Dhabi National Oil Company (ADNOC) (UAE), PT Pertamina (Persero) (Indonesia), Phillips 66 (US), Petroliam Nasional Berhad (PETRONAS) (Malaysia), GRUPA LOTOS S.A. (Poland), Sepahan Oil (Iran), GS Caltex Corporation (South Korea), and Hindustan Petroleum Corporation Limited or HPCL (India) are some of the leading players operating in the Base Oil Market. These players have adopted the strategies of agreements, expansions, new product launches, acquisitions, collaborations, contracts, investments, and divestments to enhance their position in the market.
- Process Oil Market
- Rubber Process Oil Market
Get Special Pricing on Bundle Reports:
Browse Adjacent Markets: Bulk Chemicals and Inorganics Market Research Reports & Consulting
Related Reports :
by Base Oil (Mineral Oil, Synthetic Oil, Bio-based Oil), Product Type (Engine Oil, Hydraulic Fluid, Metalworking Fluid), Application (Transportation and Industrial lubricants), Region – Global Forecast to 2024
Industrial Lubricants Market by Base oil (Mineral Oil, Synthetic Oil, Bio-based Oil), Product Type (Hydraulic Fluid, Metalworking Fluid), End-use Industry (Construction, Metal & Mining, Power Generation, Food Processing), Region – Global Forecast to 2024
Cannabis4 weeks ago
Supreme Cannabis First Quarter Earnings Release Scheduled for November 14, 2019
Cannabis4 weeks ago
Addressing THC Detox Myths and Facts
Cannabis4 weeks ago
Cannabis Can Treat Epileptic Seizures
Cannabis3 weeks ago
Khiron Launches Kuida Brand in the US, Begins First Sales
Cannabis4 weeks ago
Mastercard partners with Tappy Technologies to Embed Payment Functionality into Fashion Wearables
Cannabis2 weeks ago
Cannabis Growth Opportunity Corporation Announces NAV of $2.51
Cannabis4 weeks ago
Medicinal cannabis company Cronos Australia makes ASX debut
Cannabis4 weeks ago
Empower Clinics Announces Record Preliminary Unaudited Q3 2019 Revenue with 138% year over year increase and Details for Release of Financial Statements